15 results on '"Setnik B"'
Search Results
2. (412) Abuse potential study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone administered orally to non-dependent, recreational opioid users
3. (411) Abuse potential study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone and placebo when crushed and administered intranasally to non-dependent, recreational opioid users
4. (410) Efficacy and safety of ALO-02, an extended-release oxycodone surrounding sequestered naltrexone, in the treatment of moderate-to-severe chronic low back pain
5. (193) Prescription opioid abuse and misuse: a gap between the primary-care investigator assessment and the actual extent of these behaviors among patients with chronic pain
6. (121) Extended-release morphine sulfate and naltrexone hydrochloride: naltrexone associated effects in chronic pain patients and recreational opioid users
7. A multicenter, 12-month, open-label, single-arm, safety study of oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules (ALO-02) in patients with moderate to severe chronic non-cancer pain
8. A primary care-based, open-label study assessing the success of converting opioid experienced patients with chronic pain to EMBEDA using a standardized conversion guide, and to identify behaviors related to prescription opioid abuse, misuse, and diversion
9. Results from a chronic pain prescription opioid misuse, abuse, and diversion self-report instrument
10. The abuse potential of Remoxy ® an extended-release formulation of oxycodone
11. The abuse potential of Remoxy® an extended-release formulation of oxycodone.
12. Safety profile of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) extended release capsules in older patients.
13. Effect of tapering the dose of EMBEDA™ (morphine sulfate and naltrexone hydrochloride) extended release capsules on occurrence of withdrawal symptoms.
14. Assessment of risk of prescription opioid abuse and aberrant behaviors in the primary care setting.
15. Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.